You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (11) |
Back to Search
Exposure-response model for the effect of AZD5069, a novel CXCR2 antagonist, on neutrophil count in asthma patients
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-106-Monday
- By: WAHLBY HAMREN, Ulrika (AstraZeneca R&D, Early Clinical Development, Mölndal, Sweden)
- Co-author(s): Ulrika Wahlby Hamren: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
Justin Wilkins: Occams, Amstelveen, Netherlands;, SGS Exprimo NV, Mechelem, Belgium
Bengt Larsson: RIA TMU, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden
Marie Cullberg: Quantitative Clinical Pharmacology, Early Clinical Development, AstraZeneca R&D, Gothenburg, Sweden - Abstract:
Backgrounds
AZD5069 is a reversible oral CXCR2 antagonist that blocks neutrophil migration and reduces circulating neutrophil counts [1]. Models describing neutrophil dynamics after cytotoxic drug intervention have previously been published [2], however these are not applicable for the CXCR2 mechanism of action.Aims
We developed a population.. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026